JPWO2005105125A1 - Osteoporosis preventive or therapeutic agent - Google Patents

Abstract

The presently used preventive or therapeutic agent for osteoporosis and synthetic hormone preparations have side effects and are difficult to take as food and drink. Unlike conventional preparations, there are few side effects, and it is possible to provide drugs, pharmaceuticals, foods and drinks effective for the prevention and improvement of osteoporosis by suppressing the increase in bone resorption by daily intake as food and drink. Objective. [MEANS FOR SOLVING PROBLEMS] The present invention is an osteoporosis preventive or therapeutic agent comprising a water-soluble fraction of kudzu as an active ingredient, and a pharmaceutical or a food or drink containing the same.

Description

The present invention relates to a water-soluble fraction of the roots or stems of kudzu (kudzu, Pueraria spp.) Useful as an agent for preventing or treating osteoporosis, and a pharmaceutical and a food and drink containing the same.

The average life expectancy of Japanese is the best for both men and women in recent years, and the proportion of elderly people in the population has been increasing year by year. With the aging of the population, the number of osteoporosis patients whose bone density decreases and bones become brittle has become a major social problem. Osteoporosis is common in postmenopausal women and is a typical senile disease. When osteoporosis occurs, symptoms such as bone curvature, severe pain, and fractures are observed, and these are major causes of bedriddenness. If you stay bedridden for a long time, the risk of dementia increases, so prevention of osteoporosis and early treatment are important issues in order to increase the quality of life of the elderly. .
Examples of osteoporosis treatments include calcium preparations, active vitamin D, anabolic hormones, bone resorption inhibitors, etc. The higher the effectiveness, the narrower the difference between the safe range and the addictive range, and the more difficult it is to adjust the dosage. Many of them also have problems with safety when administered for a long time.

Isoflavones rich in leguminous plants are known to have osteoporosis prevention and amelioration effects, and for soybean, isoflavones such as daizenin and genistein have been identified as the main body of the same effect and have been reported as functional food materials (See Patent Document 1).
Kudzu (Pueraria spp.) Is a perennial leguminous vine that is native to Asia and has a high resistance to wasteland, and is the most prolific plant resource in the mid-latitude and temperate zones of the world. As food, other than root starch is not used. Kudzu is also a legume, which is presumed to have a high isoflavone content, verified the osteoporosis effect of kudzu itself, and the use of therapeutic agents as drugs has already been reported (Patent Document 2). However, there has been no example of clarifying the function of the extract so far, and it has not been clear which substance of the isoflavones is the main body of the effect.
Japanese Patent Laid-Open No. 9-309902 JP 2003-95971 A

Under such circumstances, the present invention, unlike currently used osteoporosis prevention or treatment agents and synthetic hormone preparations, has few side effects and suppresses bone resorption increase by simply ingesting as a daily food or drink. Therefore, it is intended to provide drugs, pharmaceuticals, and foods and drinks that are effective in preventing and improving osteoporosis.

As a result of diligent research to solve the above-mentioned problems, the present inventors have excellent bone resorption inhibitory action on water-soluble extracts of kudzu roots, stems and flowers that have been used as traditional Chinese medicine in Japan since ancient times. As a result, the present invention was completed.
That is, the present invention relates to an agent for preventing or treating osteoporosis characterized by containing a water-soluble extract of kudzu root, stem and flower as an active ingredient.

According to the present invention, it is a plant resource that is highly resistant to wasteland and has a strong growth potential, and is the most prosperous plant resource in the mid-latitude and temperate zones of the world. It can be used effectively. The water-soluble fraction extracted from the roots, stems, or flowers of kudzu of the present invention has a bone resorption inhibitory effect, and is useful as a food or drink or a pharmaceutical that is effective in preventing and improving menopausal disorders such as osteoporosis.

In Example 2, it is a figure which shows the result of the HPLC analysis which shows the isoflavone content of each sample of a root, a perennial stem, an annual stem, and a leaf. In Example 2, it is a figure which shows the result of the HPLC analysis which shows the isoflavone content of a flower extraction powder. It is a graph which shows the result of having verified the inhibitory effect of the ethanol extract of a kudzu root with respect to the bone resorption of an ovariectomized osteoporosis model animal by measuring the change of bone metabolism markers Pyr and Dpyr. It is a graph which shows the result of having verified the inhibitory effect of the ethanol extract of a perennial stem of Kudzu on the bone resorption of an ovariectomized osteoporosis model animal by measuring the change of bone metabolism markers Pyr and Dpyr. Results of verifying the inhibitory action of puerarin, which is abundant in the extract of kuzu root and stem, on bone resorption in ovariectomized osteoporosis model animals by measuring changes in bone metabolism markers Pyr and Dpyr Is a graph showing

Therefore, the present inventors have started the present invention because it is possible to use as an effective food material by clarifying the osteoporosis preventive or therapeutic effect of isoflavones in the waste component and establishing an effective preparation method of the active ingredient. Other than roots, for example, from the idea of whether active ingredients can be prepared from other tissues, such as native stalks that have been left or discarded, each one from the roots, leaves, annual stems, perennial stems and flowers of kuzu The water-soluble fraction was extracted, the bone metabolism inhibitory action was investigated, and the root and stem extract was found to have an excellent osteoporosis prevention and treatment action. Furthermore, fraction purification was carried out, and it was revealed that the active main body is isoflavones, particularly puerarin, which is a component specific to kudzu, and the present invention has been completed based on this finding.

The water-soluble fraction of the present invention is produced by cutting or crushing the roots or stems of flowers or the dried or dried flowers, or by extracting them with a suitable solvent. Examples of the extraction solvent include hydrophilic solvents such as water, ethanol, methanol propanol, acetone, and tetrahydrofuran, and these may be used alone or in combination of two or more. In particular, water and ethanol alone or a mixed solvent system obtained by mixing these in an arbitrary ratio is preferable from the viewpoint of safety.
The extraction conditions can be arbitrarily determined. For example, extraction can be performed simply by immersing the crushed stalks of kudzu in an extraction solvent about 3 to 5 times at room temperature or under heating for 1 to 5 hours. The extract may be used as it is after removing solids by filtration or centrifugation, but the extraction solvent may be distilled off by a known appropriate method and used as an extract or dried. It can also be used.
Kuzu-derived starch is a well-known food material, but its production is refined by adding water to the root of kudzu and repeating the operations of suspension, precipitation, and separation. . During this processing process, it is also possible to produce the exposed water as an extract.

Regarding the active ingredient in the water-soluble fraction showing the osteoporosis preventive and therapeutic action of the present invention, it is expected to be isoflavones because the waste is a bean plant. In fact, the present inventors have confirmed that 10-50% by weight ratio in the water-soluble fraction is isoflavones. The composition of isoflavones includes daizin and genistin, which are also contained in soybeans, but is characterized by the presence of 30% to 90% by weight of puerarin, a peculiar component of kudzu. is there.
The water-soluble fraction having an osteoporosis prevention and treatment action of the present invention can be administered over a wide range of volumes, and is usually 0.01 mg to 1000 mg, preferably 1 mg to 1 kg body weight in terms of extract solids. Is 5 mg to 50 mg, but is appropriately determined in consideration of the sex, age, weight, etc. of the administered substance.

As a food or drink for osteoporosis prevention or treatment characterized by containing the water-soluble fraction of the waste of the present invention as an active ingredient, beverages such as juice, health tea, milk beverage, lactic acid beverage, coffee beverage, yogurt, Examples include various forms such as jelly, gum, candy, ice, noodles, granules, capsules, tablet confectionery and other confectionery, health foods, and the like. Further, the blending amount varies depending on the preparation form and expected degree of osteoporosis prevention or treatment, but it is preferably used at a concentration at which the taste of the material itself does not adversely affect the food. Usually, it is appropriate to blend 0.01 to 10.0% by weight, preferably 0.1 to 5.0% by weight. However, if there is no problem with the taste of the food, it is not limited to this range. Furthermore, according to a conventional method, a lubricant, an emulsifier, a suspending agent, an antioxidant, a sweetener, a flavoring agent, and the like can be added.
EXAMPLES Next, although an Example and a test example are given and this invention is demonstrated further in detail, this invention is not limited to these.

[Production Example 1] Production of Kudzu ethanol extract powder Each 500 g of dried Kudzu root and dried perennial stalk was cut with scissors or a kitchen knife, ground with a potter type homogenizer, passed through a 30 mesh sieve, and fine powder It was. This fine powder was stirred in 3.5 times (W / V) 99.5% ethanol at 25 ° C. for 1 hour, extracted, and then centrifuged at 3000 rpm for 30 minutes to obtain the alcohol-soluble fraction of the supernatant. Obtained. This soluble fraction was concentrated under reduced pressure and lyophilized to obtain 25 g of powder from the dried roots and 15 g of dried perennial stems, each of which was used as an ethanol-extracted powder.
[Production Example 2] Manufacture of powder of methanol extract of kudzu 15 g of dried flowers of kudzu were immersed in 150 ml of 100% methanol (or water), extracted at room temperature for 4 hours, and filtered. Further, the residue was extracted twice with methanol (or water), and the resulting solutions were combined, concentrated under reduced pressure, and lyophilized. 1.47 g of powder was obtained from methanol and 3.58 g of powder was obtained from water, which were used as a methanol extract powder and a water extract powder, respectively.

[Content of isoflavones in the extract]
Example 1 [Manufacturing Example 1] kudzu root and perennial stem ethanol extract powder, annual stem and leaf ethanol extract powder prepared in the same manner as Example 1, 99.5% of Example 1 A solution obtained by dissolving each of the root, perennial stem, annual stem and leaf extract powders prepared in the same manner by replacing ethanol with water in 70% ethanol and filtering was subjected to HPLC analysis under the following conditions. The result is shown in FIG. Although it did not reach the roots, it was found that perennial stems contained a large amount of isoflavones.
Moreover, the solution obtained by melt | dissolving and filtering the methanol extraction powder | flour and water extraction powder | flour of the flower of the flower of Example 1 [manufacture example 2] in 70% ethanol was used for the HPLC analysis similarly. The result is shown in FIG. Although it did not reach the roots and stems, it was found that the flowers also contain isoflavones.
[HPLC analysis conditions]
Column: Inertsil ODS-3
(250mm × 4.6mmI.D., 5μm, manufactured by GL-Science)
It was attached to a guard column (50 mm x 4.6 mm ID).
Eluent: A-10% acetonitrile aqueous solution (containing 0.1% formic acid)
B-35% acetonitrile aqueous solution (containing 0.1% formic acid)
Gradient condition:
A: B = 100: 0 → 15: 75 (0-60min)
15: 75 → 0: 100 (60-70min)
0: 100 → 0: 100 (70 ~ 85min)
Column temperature: 45 ° C
Flow rate: 1.0ml / min
Detector: UV260nm

[Production Example 3] Production of extract from waste starch bleaching water 1000 ml of "bleaching water" which is waste water generated during the production of waste starch is filtered, and space velocity = 1, normal temperature in a column packed with styrene synthetic adsorption resin The liquid was passed through. Subsequently, after washing the column by passing 2 column volumes or more of pure water, 65% ethanol was similarly passed 3 column volumes or more to elute polyphenols. The eluate collected with the ethanol solution was concentrated under reduced pressure and lyophilized to obtain 9.56 g of a dried extract containing 34.1% isoflavones composed of 80% or more of puerarin.

[Pharmacological Test Example 1] Osteoporosis model animal bone resorption inhibitory action by ethanol extract powder of kudzu root An osteoporosis model mouse can be prepared by extracting the ovaries of female ddy mice over 10 weeks of age (Endocrinology, vol. 140, page 1893-1900 (1999)). A sham mouse was prepared as a control.
After acclimation for 2 weeks after the operation, 7 to 8 oophorectomy group, control group and other mice were bred one by one in a metabolic cage, and urine was collected every day. Thereafter, the amount of pyridinoline (pyridinoline, Pyr) and deoxypyridinoline (depypyridinoline, Dpyr), which are bone metabolism markers in urine, was measured for each group.
After confirming that Pyr and Dpyr excretion into the urine accompanying ovariectomy was promoted, that is, the appearance of osteoporosis symptoms, the ethanol extract of kudzu root described in Example 1 was dissolved in distilled water and orally used for mice. It was orally administered at a dose of 50 mg / kg body weight once a day with a sonde for 2 weeks. As a diet, a general mouse sample was freely ingested. The urine of these mice was collected daily and the amount of Pyr and Dpyr excreted in the urine was quantified.
The results are as shown in FIG. That is, Pyr and Dpyr, which increased to about 3 times the original level in 4 weeks after ovariectomy, decreased from the second day of administration as a result of oral administration of 50 mg / kg body weight of stalk ethanol extract per day. It started and returned to the original level after a week. The administration was further stopped after one week, and the urinary Pyr and Dpyr levels were quantified. This effect persisted even after cessation, and the effect persisted for about 3 months with respect to urinary Pyr.
Thereafter, urinary Pyr and Dpyr increase again. When this re-elevation reaches 3 times the original normal level, the second dose at a dose of 50 mg / kg results in urinary Pyr and Dpyr levels. In each case, the value began to decrease from the second day, and returned to the original normal value from the fourth to sixth days. Therefore, it was proved that oral administration of the ethanol extract of kudzu root has the effect of returning the bone resorption of osteoporosis model mice to a normal level.
On the other hand, after ovariectomy, the Pyr and Dpyr levels remained high in the mice group not administered with the litter, compared to the administered mice.
Since body weight and food intake did not change much in any group, the rate of change in Pyr and Dpyr is not likely to be affected by the effects of Kuzu administration.

[Pharmacological Test Example 2] Osteoporosis model mouse was produced by the method shown in Example 4 [Pharmacological Test Example 1] of osteoporosis model animals by using an alcohol extract powder of perennial stems of kudzu. That is, the ovariectomy was carried out on the 98th day after birth, and after 3 weeks of breeding, Pyr and Dpyr in urine were measured for 3 weeks. Pyr and Dpyr following oophorectomy progressed into the urine, that is, after confirming the appearance of osteoporosis symptoms. Dissolve the perennial stem ethanol extract of kudzu in distilled water for 2 weeks. Oral sonde was given once daily at a dose of 20 mg / kg body weight for 2 weeks (7 animals in the 20 mg / kg group, 8 animals in the 50 mg / kg group). As a diet, a general mouse sample was freely ingested. The urine of these mice was collected daily and the amount of Pyr and Dpyr excreted in the urine was quantified.
At the same time, as a control, urinary Pyr and Dpyr were measured in a group (7 mice) in which only distilled water was orally administered to ovariectomized mice and a sham operated mouse group (Sham mice: 7 mice).
The results are as shown in FIG. That is, Pyr and Dpyr, which increased to about 3 times the original level in 6 weeks after ovariectomy, were orally administered with an ethanol extract of perennial stems of kudzu described in Example 1 per day and 20 and 50 mg per kg body weight. As a result, it started to decrease from the second day of administration and returned to the original level after four days. The administration was stopped after further administration for 10 days, and urinary Pyr and Dpyr levels were quantified. When the administration was stopped, both Pyr and Dpyr increased after a short period.
Therefore, it was proved that oral administration of an ethanol extract of perennial stems of kudzu has the effect of returning bone resorption to normal levels in osteoporosis model mice in a dose-dependent manner. On the other hand, after ovariectomy, the level of Pyr and Dpyr remained high in the group of mice that did not receive kudzu, compared to the mice that received it.
Since body weight and food intake did not change much in any group, the rate of change in Pyr and Dpyr is not likely to be affected by the effects of Kuzu administration.

[Pharmacological test example 3] Bone resorption inhibitory action of osteoporosis model animal by puerarin (Example 3) Used in Example 5 [Pharmacological test example 2], ovariectomy was performed on the 98th day after birth, and ethanol extract of perennial stems of kudzu The effect of administration of puerarin, which is the main component of isoflavone in the extract, was confirmed using mice that stopped oral administration. After confirming that the urinary Pyr and Dpyr levels reached high levels, puerarin (7 mice in the 5 mg / kg group) was orally administered continuously from the 240th day after birth.
The results are as shown in FIG. That is, from the second day after administration, it was confirmed that the amount of urinary Pyr began to decrease significantly and returned to the original level. The amount of urinary Dpyr was also slightly increased and decreased in the control group, but it was confirmed that the urine Dpyr decreased from the second day of administration in the puerarin administration group.

[Tablets and capsules]
A total of 10.0 g of 5.5 g of the extract of kudzu root used in Example 5, 4.1 g of crystalline cellulose, 0.2 g of fine silicon dioxide, and 0.2 g of sucrose fatty acid ester And were made into tablets and capsules according to a conventional method.

[Fruit juice drink]
0.45 g of ethanol extract of perennial stalks of kudzu used in Example 5, 15.0 g of transparent apple juice, 5.0 g of fructose, 0.2 g of citric acid, 2.0 g of fragrance, 0.15 g of pigment, sodium ascorbate A fruit juice drink was produced with 0.05 g, 77.15 ml of water, and the composition of each of the above components.

[Tea drink]
A tea beverage was prepared from the composition of the perennial stalk ethanol extract used in Example 5, 2 g of ethanol extract, 10 g of green tea powder, 0.3 g of sodium ascorbate, 1000 ml of hot water, and the above components.

Claims (11)

An osteoporosis preventive or therapeutic agent comprising a water-soluble fraction of kudzu as an active ingredient. The water-soluble fraction of kudzu is obtained by concentrating an extract obtained by extracting kudzu root with water, a mixture of water and a hydrophilic solvent, or a hydrophilic solvent, and further drying it. The osteoporosis preventive or therapeutic agent according to Item 1. The water-soluble fraction of kudzu is obtained by concentrating an extract obtained by extracting kudzu stalks with water, a mixture of water and a hydrophilic solvent, or a hydrophilic solvent, and further drying. The osteoporosis preventive or therapeutic agent according to Item 1. The water-soluble fraction of kudzu is obtained by concentrating an extract obtained by extracting kuzu flowers with water, a mixture of water and a hydrophilic solvent, or a hydrophilic solvent, and further drying the extract. The osteoporosis preventive or therapeutic agent according to Item 1. The osteoporosis preventive or therapeutic agent according to any one of claims 2 to 4, wherein the hydrophilic solvent is ethanol, methanol, propanol, acetone or tetrahydrofuran. 4. The osteoporosis preventive or therapeutic agent according to claim 3, wherein the stalk stem is a perennial stem that has grown for more than one year. The osteoporosis preventive or therapeutic agent according to claim 1, wherein the water-soluble fraction of kudzu is obtained by concentrating and drying dried water obtained in the process of producing kudzu starch. The agent for preventing or treating osteoporosis according to any one of claims 1 to 7, wherein the active ingredient of the water-soluble fraction of kudzu is isoflavone. The osteoporosis preventive or therapeutic agent according to claim 8, wherein the isoflavone contains 30% or more of puerarin. A food or drink containing the osteoporosis preventive or therapeutic agent according to any one of claims 1 to 9. A pharmaceutical comprising the osteoporosis preventive or therapeutic agent according to any one of claims 1 to 9.